Scolaris Content Display Scolaris Content Display

Comparison 1 Main analysis for Cisapride vs placebo, Outcome 1 'Worse, same or slight improvement' vs 'moderate or excellent improvement'.
Figures and Tables -
Analysis 1.1

Comparison 1 Main analysis for Cisapride vs placebo, Outcome 1 'Worse, same or slight improvement' vs 'moderate or excellent improvement'.

Comparison 1 Main analysis for Cisapride vs placebo, Outcome 2 Reflux index.
Figures and Tables -
Analysis 1.2

Comparison 1 Main analysis for Cisapride vs placebo, Outcome 2 Reflux index.

Comparison 1 Main analysis for Cisapride vs placebo, Outcome 3 Adverse events.
Figures and Tables -
Analysis 1.3

Comparison 1 Main analysis for Cisapride vs placebo, Outcome 3 Adverse events.

Comparison 2 Main analysis for Cisapride vs Gaviscon/Carobel, Outcome 1 'Worse, same or slight improvement' vs 'moderate or excellent improvement'.
Figures and Tables -
Analysis 2.1

Comparison 2 Main analysis for Cisapride vs Gaviscon/Carobel, Outcome 1 'Worse, same or slight improvement' vs 'moderate or excellent improvement'.

Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 1 Best case scenario.
Figures and Tables -
Analysis 3.1

Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 1 Best case scenario.

Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 2 Worst case scenario.
Figures and Tables -
Analysis 3.2

Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 2 Worst case scenario.

Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 3 Change in outcome definition: 'any symptoms' vs 'no symptoms' at end of treatment.
Figures and Tables -
Analysis 3.3

Comparison 3 Sensitivity analyses for Cisapride vs placebo, Outcome 3 Change in outcome definition: 'any symptoms' vs 'no symptoms' at end of treatment.

Comparison 1. Main analysis for Cisapride vs placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 'Worse, same or slight improvement' vs 'moderate or excellent improvement' Show forest plot

7

236

Odds Ratio (M‐H, Random, 95% CI)

0.34 [0.10, 1.19]

2 Reflux index Show forest plot

5

176

Mean Difference (IV, Random, 95% CI)

‐6.49 [‐10.13, ‐2.85]

3 Adverse events Show forest plot

4

190

Odds Ratio (M‐H, Random, 95% CI)

1.86 [0.88, 3.93]

Figures and Tables -
Comparison 1. Main analysis for Cisapride vs placebo
Comparison 2. Main analysis for Cisapride vs Gaviscon/Carobel

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 'Worse, same or slight improvement' vs 'moderate or excellent improvement' Show forest plot

1

50

Odds Ratio (M‐H, Random, 95% CI)

3.26 [0.93, 11.38]

Figures and Tables -
Comparison 2. Main analysis for Cisapride vs Gaviscon/Carobel
Comparison 3. Sensitivity analyses for Cisapride vs placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Best case scenario Show forest plot

7

290

Odds Ratio (M‐H, Random, 95% CI)

0.21 [0.08, 0.54]

2 Worst case scenario Show forest plot

7

290

Odds Ratio (M‐H, Random, 95% CI)

0.70 [0.18, 2.65]

3 Change in outcome definition: 'any symptoms' vs 'no symptoms' at end of treatment Show forest plot

4

139

Odds Ratio (M‐H, Random, 95% CI)

0.19 [0.07, 0.51]

Figures and Tables -
Comparison 3. Sensitivity analyses for Cisapride vs placebo